Last reviewed · How we verify
HBVAXPRO vaccine
HBVAXPRO is a recombinant hepatitis B surface antigen (HBsAg) vaccine that stimulates the immune system to produce antibodies against hepatitis B virus.
HBVAXPRO is a recombinant hepatitis B surface antigen (HBsAg) vaccine that stimulates the immune system to produce antibodies against hepatitis B virus. Used for Prevention of hepatitis B infection in adults and children.
At a glance
| Generic name | HBVAXPRO vaccine |
|---|---|
| Sponsor | Henogen |
| Drug class | Recombinant protein vaccine |
| Target | Hepatitis B surface antigen (HBsAg) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains recombinant HBsAg produced in yeast cells, which triggers both humoral and cellular immune responses to prevent hepatitis B infection. Upon vaccination, the immune system recognizes the foreign antigen and generates protective antibodies (anti-HBs) and memory B cells that provide long-term immunity against hepatitis B virus exposure.
Approved indications
- Prevention of hepatitis B infection in adults and children
Common side effects
- Injection site pain or soreness
- Fatigue
- Headache
- Myalgia
- Low-grade fever
Key clinical trials
- Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection (PHASE1, PHASE2)
- The COMBAT HBV Feasibility Trial (PHASE4)
- Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults (PHASE1)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies (PHASE3)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HBVAXPRO vaccine CI brief — competitive landscape report
- HBVAXPRO vaccine updates RSS · CI watch RSS
- Henogen portfolio CI